ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Levetiracetam

Also written as “Levetiracetam (Keppra)”, “levetiracetam” and “Levetiracetam 250 mg”.

Its studies are mostly in Epilepsy · Epilepsies, Partial · Seizures · Cognitive Dysfunction · Epilepsy, Generalized, led by 8 companies.

Drug pageLevetiracetam: every studyMany companies study it; this page follows only the 72 they lead. All 204 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 8, 200572 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
UCB570 open or runningphase 4since Sep 8, 2005Mar 3, 2005none ahead
Hikma Pharmaceuticalsits history only40 open or runningno phasesince Jan 15, 2009Jan 15, 2009none ahead
Teva Pharmaceutical Industriesits history only40 open or runningphase 1since Feb 20, 2009Feb 20, 2009none ahead
AgeneBioits history only20 open or runningphase 3since Mar 28, 2018Mar 28, 2018none ahead
Dr. Reddy's Laboratoriesits history only20 open or runningphase 1since May 26, 2010May 26, 2010none ahead
Ache Laboratorios Farmaceuticosits history only10 open or runningphase 3since Jul 6, 2011Jul 6, 2011none ahead
Desitin Arzneimittelits history only10 open or runningphase 1since Dec 1, 2025Dec 1, 2025none ahead
Novartisits history only10 open or runningphase 1since Jul 24, 2009Jul 24, 2009none ahead

Also a collaborator on its studies: PRA Health Sciences and Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of UCB only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 41 studies since Mar 3, 2005.

  1. Oct 22, 2010Phase 3 study in EpilepsyNCT01228747 · 361 enrolled · China, Japan
  2. Oct 26, 2010Phase 4 study in EpilepsyNCT01229735 · 343 enrolled · Korea, Republic of
  3. Feb 8, 2011Phase 3 study in EpilepsyNCT01292837 · 13 enrolled · Japan
  4. May 9, 2011Phase 3 study in Epilepsies, PartialNCT01375374 · 11 enrolled · Austria, Germany, Spain
  5. Jul 12, 2011Phase 1 study in Healthy VolunteersNCT01394224 · 25 enrolled · United Kingdom
  6. Jul 13, 2011Phase 3 study in EpilepsyNCT01398956 · 44 enrolled · Japan
  7. Jul 29, 2011Phase 2 study in EpilepsyNCT01407523 · 16 enrolled · Japan
  8. Dec 9, 20112 phase 4 studiesNCT01491113, NCT01498822
  9. Jan 5, 2012Phase 3 study in EpilepsyNCT01506882 · 71 enrolled · Japan
  10. Jun 11, 20122 phase 1 studies in Human VolunteersNCT01618903, NCT01618877
  11. Nov 7, 2012Phase 1 study in Healthy VolunteersNCT01725009 · 32 enrolled · Japan
  12. Sep 26, 2013Phase 3 study in EpilepsyNCT01954121 · 436 enrolled · China
  13. Nov 6, 2015Phase 1 study in Healthy VolunteersNCT02602860 · 13 enrolled · United States
  14. Nov 8, 2017Phase 3 study in SeizuresNCT03340064 · 38 enrolled · Japan

TargetBeta

“Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker”ChEMBL 37, by rule

Studies

All 57 UCB leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03340064Seizures · Japan3CompletedJun 1, 202138
NCT02602860Healthy Volunteers · United States1CompletedSep 201713
NCT01954121Epilepsy · China3CompletedSep 2015436
NCT01725009Healthy Volunteers · Japan1CompletedDec 201232
NCT01618903Human Volunteers · China1CompletedJul 201224
NCT01618877Human Volunteers · China1CompletedJul 201224
NCT01506882Epilepsy · Japan3CompletedOct 201371
NCT01498822Epilepsy · Korea, Republic of4CompletedJul 2014353
NCT01491113Healthy Subjects · Japan4CompletedNov 201230
NCT01407523Epilepsy · Japan2CompletedFeb 201216
NCT01398956Epilepsy · Japan3CompletedApr 201644
NCT01394224Healthy Volunteers · United Kingdom1CompletedSep 201125
NCT01375374Epilepsies, Partial · Austria, Germany, Spain3TerminatedMar 201311
NCT01292837Epilepsy · Japan3CompletedJun 201313
NCT01229735Epilepsy · Korea, Republic of4CompletedMay 2015343
NCT01228747Epilepsy · China, Japan3CompletedApr 2014361
NCT01063764Epilepsy · Japan3CompletedApr 201173
NCT00985348Healthy · United Kingdom1CompletedOct 200926
NCT00961441Epilepsy · United States2CompletedMar 201025
NCT00631150Epilepsy4CompletedJul 200435
NCT00630968Epilepsy4CompletedFeb 20041,541
NCT00630630Epilepsy4CompletedNov 20033
NCT00630357Epilepsy4CompletedJul 200414
NCT00643500Epilepsies, Partial4CompletedMay 2003342
NCT00615615Epilepsy3CompletedMar 2003216
NCT00610454Epilepsy2CompletedAug 200425
NCT00612859Anxiety Disorders2CompletedJun 2004217
NCT00600509Epilepsy2CompletedJul 2003216
NCT00545012Seizures2CompletedMay 20034
NCT00544050Epilepsy2CompletedMay 200313
NCT00535392Epilepsy · United States, Belgium, France and more2CompletedFeb 201033
NCT00505934Epilepsy · United States, Belgium, France and more2CompletedMar 201019
NCT00419393Epilepsy · United States, Mexico, Poland and more3CompletedMar 2010190
NCT00419094Epilepsy · United States, Mexico, Poland and more3CompletedSep 2009228
NCT00367432Epilepsy · Japan3CompletedDec 2010398
NCT00368069Epilepsy · Brazil, Finland, India and more3CompletedMay 2007158
NCT00291655Epilepsy · Belgium, Bulgaria, Finland and more3CompletedApr 2008130
NCT00280696Epilepsies, Partial · Japan3CompletedNov 2007352
NCT00245713Epilepsies, Partial4CompletedNov 200440
NCT00175955Dyskinesia, Drug-Induced · Belgium, Bulgaria2CompletedDec 200570
NCT00175903Epilepsy · Australia, Austria, Belgium and more3CompletedOct 20071,701
NCT00175890Epilepsies, Partial · United States, Argentina, Belgium and more3CompletedJan 2007116
NCT00160654Epilepsies, Partial · Hong Kong, Malaysia, Philippines and more4CompletedDec 12, 2006251
NCT00160628Epilepsies, Partial3CompletedOct 2004100
NCT00160615Epilepsies, Partial3CompletedJan 17, 2007154
NCT00160576Parkinson Disease2CompletedNov 200430
NCT00160550Epilepsy, Generalized3CompletedJun 2005154
NCT00160511Neuralgia, Postherpetic2CompletedAug 2005170
NCT00152516Epilepsies, Partial · United States, Belgium, Brazil and more3CompletedJun 2008255
NCT00152373Epilepsies, Partial3CompletedMay 2005192
NCT00150813Epilepsy, Tonic-Clonic · Czechia, Hungary, Poland and more3CompletedMay 29, 200766
NCT00150787Epilepsy, Tonic-Clonic3CompletedNov 2005250
NCT00150774Epilepsy, Generalized3CompletedDec 2004116
NCT00150748Epilepsy, Generalized3CompletedJul 2007217
NCT00150735Epilepsy, Generalized3CompletedJul 2005580
NCT00150709Epilepsies, Partial3CompletedJan 25, 2006223
NCT00105040Epilepsies, Partial · United States, Canada, South Africa2CompletedMar 200787

How it is read

Names in the registry

  • “Levetiracetam”, 52 entries
  • “Levetiracetam (Keppra)”, 4 entries
  • “levetiracetam”, 3 entries
  • “Levetiracetam 250 mg”, 3 entries
  • “Levetiracetam 500 mg”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.